Hexarelin
Also called Examorelin, EP-23905, MF-6003.
Hexarelin has no FDA-approved product. This page cites 2 sources, and the strongest evidence comes from human trials.
- Status
- No FDA-approved product
- Form
- Injection
- Half-life
- Not modeled
- Strongest evidence
- Human trials
- Cited claims
- 2
- Last updated
- November 6, 2026
What the evidence says
Each claim names the kind of study behind it, what it can't tell you, and where it comes from.
Human trials
A double-blind, placebo-controlled study in 12 healthy adult men found that single intravenous administrations of hexarelin increased circulating growth hormone in a dose-dependent manner.
Limits: This was an acute hormone-response experiment, not a trial of muscle gain, recovery, or longevity. A rise in growth hormone does not establish benefit or long-term safety, and intravenous results do not validate other formulations.
Human trials
In a placebo comparison involving seven healthy young volunteers, repeated nighttime hexarelin administration reduced stage 4 sleep and delta power while increasing several circulating hormones.
Limits: The study was small and short. It does not establish a chronic sleep disorder or quantify long-term risk, but its measured sleep findings do not support claims that hexarelin reliably improves deep sleep.
Regulatory status
United States
No FDA-approved product was identified in current ingredient searches for hexarelin or examorelin. The FDA substance registry confirms these names describe the same molecule, but registration is not approval. Hexarelin is absent from the October 2026 HHS peptide policy appendix.